Most of the time, treatment of bladder cancer is based on the tumor’s clinical stage when it's first diagnosed. Stage means how deep it's thought to have grown into the bladder wall and whether it has spread beyond the bladder. Other factors, such as the size of the tumor, how fast the cancer cells are growing (grade ), and a person’s ...
The overall approach to the treatment of metastatic urothelial carcinoma is summarized here. For patients with a good performance status, adequate renal function, and metastatic or inoperable locally advanced urothelial cancer, we recommend initial treatment using cisplatin-based combination chemotherapy .
Papillary urothelial carcinoma is a type of bladder cancer. It is often slow growing, and effective treatment is possible in many cases. Find out more.
Platinum-based combination chemotherapy has been the standard of care in the first-line treatment of metastatic urothelial carcinoma (mUC). Treatment of metastatic disease following progression on platinum-based regimens has evolved significantly in the last few years.
Treatment options for bladder cancer depend on a number of factors, including the type of cancer, grade of the cancer and stage of the cancer, which are taken into consideration along with your overall health and your treatment preferences. Bladder cancer treatment may include: Surgery, to remove cancerous tissue
Papillary urothelial carcinoma is a type of bladder cancer. It starts in urothelial cells in the bladder lining. Urothelial cells also line the urethra, ureters, and other parts of the urinary tract.
Bladder cancer treatment options depend on if it is nonmuscle or muscle invasive and may include surgery, BCG, chemotherapy, and targeted therapy. Get detailed information about the diagnosis and treatment of newly diagnosed and recurrent bladder cancer in this summary for clinicians.
Urothelial Cancer. In the United States in 2016, it is estimated that there will be 76,960 new diagnoses of bladder cancer, with approximately 16,390 deaths. Urothelial cancers encompass carcinomas of the bladder, ureters, and renal pelvis, which occur at a ratio of 50:3:1, respectively. Cancer of the urothelium is a multifocal process.
Treatments for metastatic urothelial cancer are expanding due to the number of immunotherapies available to patients and physicians, but the paradigm for patient treatment needs to be refined according to Dr. Daniel P. Petrylak. There have been several immune checkpoint inhibitors (ICI’s) approved ...
Bladder cancer is the most common type of urothelial carcinoma, and up to half of all people with the advanced form of the disease are unable to receive cisplatin chemotherapy as an initial treatment and therefore have a high unmet medical need. Urothelial carcinoma also includes cancers of the urethra, ureters and renal pelvis.